

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIODNER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/767,421	01/22/2001	Michael J. Shamblott	JHU1750-1	9551
LISA A. HAIL	7590 01/14/200 E. Ph.D .	EXAMINER		
GRAY CARY WARE & FREIDENRICH LLP Suite 1100 4365 Executive Drive			CROUCH, DEBORAH	
			ART UNIT	PAPER NUMBER
San Diego, CA	92121-2133	1632		
			MAIL DATE	DELIVERY MODE
			01/14/2009	PAPER

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

Advisory Action Before the Filing of an Appeal Brief

Application No.	Applicant(s)	
09/767,421	SHAMBLOTT ET AL.	
Examiner	Art Unit	
Deborah Crouch	1632	

	Beberan ereach	1002	
The MAILING DATE of this communication app	ears on the cover sheet with the	correspondence add	ress
THE REPLY FILED 06 January 2009 FAILS TO PLACE THIS	APPLICATION IN CONDITION FO	R ALLOWANCE.	
 The reply was filed after a final rejection, but prior to or or application, applicant must timely file one of the following application in condition for allowance; (2) a Notice of App for Continued Examination (RCE) in compliance with 37 of periods: 	replies: (1) an amendment, affidavieal (with appeal fee) in compliance	it, or other evidence, w with 37 CFR 41.31; or	hich places the (3) a Request
a) The period for reply expires 5 months from the mailing date	e of the final rejection		
b) The period for reply expires on: (1) the mailing date of this A	•	in the final rejection, which	chever is later. In
no event, however, will the statutory period for reply expire			
Examiner Note: If box 1 is checked, check either box (a) or MONTHS OF THE FINAL REJECTION. See MPEP 706.07	(f).		
Extensions of time may be obtained under 37 CFR 1.136(a). The date have been filed is the date for purposes of determining the period of extender 37 CFR 1.17(a) is calculated from: (1) the expiration date of the set forth in (b) above, if checked. Any reply received by the Office late may reduce any earned patent term adjustment. See 37 CFR 1.704(b) NOTICE OF APPEAL	tension and the corresponding amount shortened statutory period for reply orig r than three months after the mailing da	of the fee. The appropria inally set in the final Offic	ate extension fee e action; or (2) as
The Notice of Appeal was filed on A brief in compared to the state of Appeal was filed on	alianaa with 27 CED 41 27 must ba	filed within two months	of the data of
filing the Notice of Appeal (37 CFR 41.37(a)), or any extension Notice of Appeal has been filed, any reply must be filed water AMENDMENTS	ension thereof (37 CFR 41.37(e)), to	avoid dismissal of the	
3. The proposed amendment(s) filed after a final rejection,	but prior to the date of filing a brief.	will not be entered be	cause
(a) They raise new issues that would require further co			
(b) They raise the issue of new matter (see NOTE belo		,,	
(c) ☐ They are not deemed to place the application in be appeal; and/or	tter form for appeal by materially re	ducing or simplifying th	ne issues for
(d) ☐ They present additional claims without canceling a	corresponding number of finally reje	ected claims.	
NOTE: See Continuation Sheet. (See 37 CFR 1.7	116 and 41.33(a)).		
4. The amendments are not in compliance with 37 CFR 1.1	21. See attached Notice of Non-Co	mpliant Amendment (I	PTOL-324).
5. Applicant's reply has overcome the following rejection(s)			
 Newly proposed or amended claim(s) would be a non-allowable claim(s). 	llowable if submitted in a separate,	timely filed amendmer	t canceling the
7. For purposes of appeal, the proposed amendment(s): a) how the new or amended claims would be rejected is pro The status of the claim(s) is (or will be) as follows: Claim(s) allowed:		ll be entered and an ex	xplanation of
Claim(s) objected to:			
Claim(s) rejected: <u>1,10,13,15,16,22,23,25-29,32 and 35-</u> . Claim(s) withdrawn from consideration:	<u>38</u> .		
AFFIDAVIT OR OTHER EVIDENCE			
 The affidavit or other evidence filed after a final action, be because applicant failed to provide a showing of good an was not earlier presented. See 37 CFR 1.116(e). 			
9. The affidavit or other evidence filed after the date of filing entered because the affidavit or other evidence failed to showing a good and sufficient reasons why it is necessar	overcome <u>all</u> rejections under appea	al and/or appellant fails	s to provide a
10. ☐ The affidavit or other evidence is entered. An explanation REQUEST FOR RECONSIDERATION/OTHER	on of the status of the claims after e	ntry is below or attach	ed.
11. The request for reconsideration has been considered by See Continuation Sheet.	ut does NOT place the application in	n condition for allowan	ce because:
 12. ☐ Note the attached Information <i>Disclosure Statement</i>(s). 13. ☐ Other: . 	(PTO/SB/08) Paper No(s)		
	/Deborah Crouch/ Primary Examiner, Art U	Jnit 1632	
	=		

Continuation of 3. NOTE: Amendments to claim 22, lacking LIF, 30 population doublings without being immortal, each raise new issues for further search and consideration for art and/or new matter.

Continuation of 11. does NOT place the application in condition for allowance because:

Applicant argues Hogan did not produce EB-derived cells. Applicant argues Hogan produces EG cells, not EB cells.

The following is an Hogan, col. 8, lines 38-49: "Four independent lines of undifferentiated cells derived from 8.5 day embryos and cultured onto STO feeder layers were trypsinized and pipetted gently to generate small clumps of cells which were then placed in bacteriological plastic dishes. After five to seven days most of the clumps differentiated into typical simple or cystic embryoid bodies (EBs), with a clear outer layer of extraembryonic endoderm cells (FIGS. 4, B). When these EBs were returned to tissue culture plastic dishes they rapidly attached and over two weeks gave rise to a variety of cell types, including extraembryonic endoderm, spontaneously contracting muscle, nerve and endothelial and fibroblast-like cells.

The plated EB's produced a culture of EB-dervived cells. Thus Hogan, while teaching EG cells, also teaches EB-derived cells.